首页> 外国专利> COMPOSITION FOR TREATING OCULAR DISORDERS SUCH AS MACULAR DEGENERATION, RETINOPATHY AND GLAUCOMA

COMPOSITION FOR TREATING OCULAR DISORDERS SUCH AS MACULAR DEGENERATION, RETINOPATHY AND GLAUCOMA

机译:用于治疗黄斑变性,视网膜病变和青光眼等眼部疾病的组合物

摘要

A method for treating choroidal neovascularization in a patient includes administrating as eye drops into the eye of the patient having choroidal neovascularization a therapeutically effective amount of an aqueous ophthalmic composition that is formulated for topical administration as eye drops. The aqueous ophthalmic composition consists essentially of Timolol Maleate at a concentration of about 0.1% to 0.5%, Dorzolamide at a concentration of about 0.5% to 2.5%, Prednisolone at a concentration of about 1.0% to 3.0%, Ketorolac Tromethamine at a concentration of about 0.4% to 1.2%, and sterile water at a concentration of at least about 90.0%.
机译:一种用于治疗患者的脉络膜新血管形成的方法,包括将治疗有效量的水性眼科用组合物作为滴眼剂作为滴眼剂滴入患有脉络膜新血管形成的患者的眼睛中,所述滴眼剂被配制用于局部给药。水性眼科用组合物基本上由浓度为约0.1%至0.5%的马来酸替莫洛尔,浓度为约0.5%至2.5%的多佐胺,浓度为约1.0%至3.0%的泼尼松龙,浓度为0.1%至3.0%的酮咯酸氨丁三醇组成。约0.4%至1.2%,以及无菌水的浓度为至少约90.0%。

著录项

  • 公开/公告号US2020188405A1

    专利类型

  • 公开/公告日2020-06-18

    原文格式PDF

  • 申请/专利权人 RHEOSTASIS LLC;

    申请/专利号US202016799956

  • 发明设计人 SHALESH KAUSHAL;

    申请日2020-02-25

  • 分类号A61K31/5377;A23L33/105;A23L33/10;A61K9/08;A23L33/12;A23L33/155;A23L33/16;A23L33/175;A61P27/06;A61K9;A61K45/06;A61K47/02;A61K31/407;A61K31/661;A61K31/382;

  • 国家 US

  • 入库时间 2022-08-21 11:26:42

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号